Speciality Medicines SME IPO
Speciality Medicines IPO — date, price band, lot size & details 2026
Speciality Medicines listed on 30 Mar 2026 at ₹124, flat to the ₹124 issue price.
Speciality Medicines SME IPO will open for subscription from 10 April 2026 to 15 April 2026. The company was incorporated in 2012 and operates in the pharmaceutical sector, focusing on trading and distribution of speciality and critical care medicines. It follows a distribution-driven business model, supplying products to hospitals and healthcare institutions. The company has a strong presence across major cities in India, catering to growing demand for specialised healthcare solutions.
Stock price
Speciality Medicines is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 3 October.
- Open 20 Mar 2026
- Close 24 Mar 2026
- Allotment 25 Mar 2026
- Refund/credit 27 Mar 2026
- Listing 30 Mar 2026
Issue summary
The terms of the offer, as filed.
| IPO Dates | 20 to 24 Mar, 2026 |
|---|---|
| Price Band | ₹117 – ₹124 |
| Face Value | ₹10 |
| Lot Size | 1000 Shares |
| Issue Size | ₹29 Cr |
| Sale Type | NII Shares Offered |
| Listing On | BSE SME |
| Employee Discount | Not less than 49% |
| Registrar | Skyline Financial Services Private Limited |
| Min Investment | ₹ 2,48,000 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 1000 shares at the ₹124 cut-off. The SME retail application is a fixed 2 lots; HNI starts at 3.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 2 | 2,000 | ₹2,48,000 |
| Retail (max) | 2 | 2,000 | ₹2,48,000 |
| HNI (min) | 3 | 3,000 | ₹3,72,000 |
Three years of numbers
All figures in ₹ crore, as reported in the Speciality Medicines offer document.
| Metric | 31 Oct 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 45.57 | 39.98 | 22.68 |
| Total Income | 36.93 | 58.54 | 27.66 |
| Profit After Tax | 6.06 | 8.61 | 2.93 |
| EBITDA | 6.51 | 9.09 | 5.26 |
| NET Worth | 36.47 | 30.42 | 15.06 |
| Reserves and Surplus | 30.04 | 23.98 | 9.95 |
| Total Borrowing | 4.81 | 5.05 | 2.86 |
See how this IPO compares — view listing performance of all SME IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Speciality Medicines RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Speciality Medicines IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Post-Issue |
|---|---|
| EPS (₹) | ₹11.82 |
| P/E Ratio (x) | 10.49 |
| Market Cap at Offer Price (₹ Cr) | ₹63.57 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹124 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
₹50.66 Cr of the issue is earmarked to named objects.
About the company
The company’s business model revolves around sourcing, marketing, and distribution of speciality drugs, along with a focus on quality and regulatory compliance. It offers a diverse portfolio of branded and generic medicines, targeting both domestic and selected international markets. By leveraging an asset-light approach and an efficient supply chain network, Speciality Medicines Limited aims to scale its operations while maintaining consistent product availability and expanding its reach in the healthcare ecosystem.
Interested in this IPO? Check the live subscription status or browse all upcoming SME IPOs.
+91 22 4604 5344
The bankers & the filings
Who is running the book, and the documents this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Unistone Capital
3 issues handled (2 mainboard, 1 SME)2 of their issues have listed so far, and 1 opened above the issue price (average +1.4%). That is too small a sample to read as a hit rate.
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Speciality Medicines?
The current Grey Market Premium is ₹0.
What is the Speciality Medicines IPO price band?
₹117 to ₹124, on a face value of ₹10.
When is the allotment?
The basis of allotment is 25 March 2026, with listing on 30 March 2026.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — Skyline Financial Services Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every SME and Mainboard issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
